Extended Follow-Up Of Cd4(+) T Cell Recovery Kinetics In A Large Cohort Of Patients With B-Cell Lymphoproliferative Disease Treated With Rituximab-Bendamustine

Combined with anti-CD20 monoclonal antibodies (MAb), bendamustine has historically been used as frontline therapy for chronic lymphocytic leukemia (CLL) patients unsuitable for fludarabine combinations 1,2, and for the treatment of relapsed CLL 3 and indolent non-Hodgkin lymphomas (iNHL) 4. In recent years, it has been increasingly used as initial therapy for iNHL, particularly follicular lymphoma 5-7. In 2017, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a warning highlighting the risk of prolonged lymphopenia after bendamustine based therapies 8. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.